232 related articles for article (PubMed ID: 32000236)
1. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
[TBL] [Abstract][Full Text] [Related]
2. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
3. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients.
Linder KA; Kovacs C; Mullane KM; Wolfe C; Clark NM; La Hoz RM; Smith J; Kotton CN; Limaye AP; Malinis M; Hakki M; Mishkin A; Gonzalez AA; Prono MD; Ostrander D; Avery R; Kaul DR
Transpl Infect Dis; 2021 Aug; 23(4):e13687. PubMed ID: 34251742
[TBL] [Abstract][Full Text] [Related]
4. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
Turner N; Strand A; Grewal DS; Cox G; Arif S; Baker AW; Maziarz EK; Saullo JH; Wolfe CR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642941
[TBL] [Abstract][Full Text] [Related]
5. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
6. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
7. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
8. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients.
Kachur E; Roshdy D; Hamadeh I; Dodd B; Shahid Z
Transpl Infect Dis; 2021 Apr; 23(2):e13502. PubMed ID: 33171005
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
[TBL] [Abstract][Full Text] [Related]
10. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
Veit T; Munker D; Barton J; Milger K; Kauke T; Meiser B; Michel S; Zoller M; Nitschko H; Keppler OT; Behr J; Kneidinger N
Am J Transplant; 2021 Oct; 21(10):3449-3455. PubMed ID: 34118118
[TBL] [Abstract][Full Text] [Related]
11. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
[TBL] [Abstract][Full Text] [Related]
12. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.
Veit T; Munker D; Kauke T; Zoller M; Michel S; Ceelen F; Schiopu S; Barton J; Arnold P; Milger K; Behr J; Kneidinger N
Transplantation; 2020 Feb; 104(2):410-414. PubMed ID: 31385924
[TBL] [Abstract][Full Text] [Related]
13. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
Monday LM; Keri V; Chandrasekar PH
Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
[TBL] [Abstract][Full Text] [Related]
15. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
[TBL] [Abstract][Full Text] [Related]
16. Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.
Kilgore JT; Becken B; Varga MG; Parikh S; Prasad V; Lugo D; Chang YC
J Pediatric Infect Dis Soc; 2020 Sep; 9(4):486-489. PubMed ID: 31362308
[TBL] [Abstract][Full Text] [Related]
17. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
18. Letermovir for the management of cytomegalovirus infection.
Bowman LJ; Melaragno JI; Brennan DC
Expert Opin Investig Drugs; 2017 Feb; 26(2):235-241. PubMed ID: 27998189
[TBL] [Abstract][Full Text] [Related]
19. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
20. Use of Letermovir for Primary and Secondary Cytomegalovirus Prophylaxis in Abdominal Organ Transplantation: A Single Center Experience.
Ibrahim D; Byrns J; Maziarz E; Alexander BD; Saullo JL
J Pharm Pract; 2024 Jun; 37(3):770-779. PubMed ID: 37280011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
